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FOREWORD
The Life Sciences Research Office (LSRO)4, Fed eration of American Societies for Experimental Biol ogy (FASEB), provides scientific assessments on top ics in the biomÃ©dical sciences. Reports are based upon comprehensive literature reviews and the scientific opinions of knowledgeable investigators engaged in work in relevant areas of biology and medicine. The Federation recognizes that the safety of monosodium glutamate (MSG) as a food ingredient is a recurring question of widespread interest and that FASEB's resources are particularly suited to marshalling the opinions of knowledgeable scientists to assist in this reexamination of scientific information on possible adverse reactions to monosodium glutamate.
This report was developed for the Center for Food Safety and Applied Nutrition (CFSAN), Food and Drug Administration (FDA) This study was initiated in September, 1992 . In a notice in the Federal Register of December 4, 1992, the FDA announced that, as a component of Task Order #1, FASEB was inviting data, information, and views bearing on the topic under study (Food and Drug Administration, 1992) . Accordingly, FASEB provided an opportunity for public oral presentations in an Open Meeting held on April 7 and 8, 1993, and for written submissions. Twenty-eight (28) individuals made oral presentations at the Open Meeting. Two hundred eighty-four (284) individuals and organiza tions have provided written submissions for consider ation by the Expert Panel . These individuals and organizations are listed in Chapter XIII. The LSRO wishes to express its appreciation to all individuals and organizations who have contributed materials for this study.
Task Order #1 was divided into two phases. In Phase I, an Expert Panel of three scientists reviewed the adequacy of the available literature and reports of adverse effects of MSG to address 18 questions posed by the FDA (1992) . Phase I culminated in a Tentative Report, made available for public review and com ment on February 23,1993 . The release of the Tenta tive Report was followed by the Open Meeting on April 7^, 1993, at which time interested parties sub mitted additional information and comments on the content of the Tentative Report as noted above. The full report from which this Executive Summary is derived is available from the American Institute of Nutrition, 9650 Rockville Pike, Bethesda, MD 20814 for $65.00 plus $6.00 shipping and handling ($9.00 shipping and handling for orders outside the U.S. Phase II of Task Order #1, initiated following the Open Meeting, involved an expansion of the Phase I ad hoc Expert Panel to eight members. The Phase II Panel was charged with evaluation of the available scientific literature and the materials received at the Open Meeting. The Panel met four times to assess and evaluate the available data on exposure and reports on adverse effects of MSG and hydrolyzed proteins. The Expert Panel members reviewed report drafts and provided additional documentation and evalua tion of scientific information for incorporation into the draft report.
In September, 1994, LSRO submitted a draft re port of the Expert Panel to FDA. Based on its review of that draft, FDA requested an expansion of the discussions as well as further clarification and addi tional information concerning the conclusions on the 18 questions. In addition, FDA indicated that the draft report raised several issues that needed to be ad dressed. To accomplish these additional assignments, FDA issued Task Order #7 which supplemented the Scope of Work in Task Order #1. Accordingly, the Expert Panel met a fifth time to add additional infor mation to the draft report and to expand on and clarify the conclusions and recommendations con tained in that report. The results ofthat meeting were incorporated by LSRO staff into the final report of Task Order #7. The deliberations of the Expert Panel, in response to Task Order #7, did not lead to any change in either the conclusions or the recommenda tions of the Task Order #1 draft report.
Throughout the course of the study, the Expert Panel members reviewed each draft and provided additional documentation and viewpoints for incor poration into the final report. However, the listing of these individuals in Chapter XII does not imply that the individual Panel members specifically endorse all statements in the report. The LSRO accepts respon sibility for the study conclusions and accuracy of the report.
The 
EXECUTIVE SUMMARY
The following paragraphs contain the responses of an ad hoc Expert Panel to 18 questions posed by FDA in regard to the possible role of MSG in eliciting or mediating (1) the symptom complex often referred to as the "Chinese Restaurant Syndrome"; (2) more se vere reactions such as dyspnea, asthma, or cardiac arrhythmias that could be life-threatening; (3) brain lesions or neurotoxicity; and (4) 
2.a. What serious (life-threatening) reactions have been reported to occur with oral Ingestion of MSG?
The FDA received no reports of unconscious ness, coma, or death related to ingestion of MSG. Of the 439 complaints of adverse reactions to MSG received by the FDA-ARMS as of February 8,19936, 36 (8.2%) were judged by FDA staff to be severe (e.g., difficulty breathing, changes in heart rate and/or blood pressure, chest pain).
A total of 154 anecdotal reports (letters) were received by LSRO as of July 1,1994. These included 20 potentially life-threatening reactions including: anaphylaxis (1); seizures (3); dysrhythmias (6); "con stricted throat" (1); dyspnea with head or neck edema (5); hypovolemic shock (1); and, syncope (3) all self-reported to be associated with consumption of MSG. While no cases of death have been directly attributable to MSG, the Expert Panel noted that at least 40% of anaphylaxis cases are wrongly reported (S0rensen et al., 1989) .
With few exceptions, reports of adverse reactions to MSG in the medical and scientific literature are case reports rather than experimental studies with appropriate controls. The majority of these re ported symptoms are transient and not life-threat ening.
The exception to the above are two case studies that report cardiac arrhythmia following ingestion of wonton soup (Gann, 1977; Goldberg, 1982) . While the subjects were reported to be otherwise normal adults (one male, one female), no data were provided on periods between meals and onset of symptoms or MSG content of the ingested foods. In addition to the arrhythmias, both authors refer enced the similarity of symptoms with the "Chinese Restaurant Syndrome," i.e., tingling and burning sensation in the head, chest, and arms, as reported byKwok (1968) .
The two cases of cardiac arrhythmias suggest that certain individuals may have serious adverse reac tions to consumption of foods presumed to have a high MSG content, e.g., wonton soup. It must be noted that the evidence linking these symptoms in these studies with MSG is presumptive as neither the glutamate content of the individual food or foods consumed nor the blood glutamate levels or any other corroborative evidence was presented. No case reports of cardiac arrhythmias have been re ported in the literature since these reports in 1977 and 1982. However, the absence of such case stud ies is not necessarily evidence of the absence of such cases in the general population.
The studies of Allen et al. (1987) provide scien tific evidence for a role of MSG in the onset of severe asthma in selected asthmatic patients. (See below and full report2, Chapter VII, A. for additional discussion and explanation.) b. What Is the quantity and quality of these reports?
The number of letters and reports received by the FDA-ARMS and submitted to LSRO is substan tial. The 20 potentially life-threatening reactions listed above were unsubstantiated anecdotes in let ters to LSRO and the quality of these reports was highly variable in terms of informational content.
is represents the last date for which LSRO received data from the FDA-ARMS reporting system. The Expert Panel had no basis to question the veracity of the reports; however, these accounts are essentially descriptive and are not verifiable without follow-up clinical investigations.
Further, because the FDA-ARMS and LSRO submissions were volun tary, it is difficult to predict, generalize, or make inferences about the incidence of such adverse re actions in the general population.
Case reports by Asnes (1980 ), Gann (1977 , and Goldberg (1982) described potentially serious reac tions. However, these reports can generally be char acterized by an inconsistent reporting of patient medical history, nutritional status (i.e., fed versus fasted state), condition of exposure (i.e., with or without other foods), and a lack of confirmatory evidence definitively linking the reactions to MSG.
The Expert Panel reviewed 11 available reports of the possible role of MSG ingestion on precipita tion or exacerbation of severe asthma in known asthmatic patients (full report^, Appendix Table 9 ). All of the studies reviewed contained design flaws or presented insufficient evidence to characterize the patient sample adequately. The most consistent problem was related to either the continuation or discontinuation of medications. The continuation of drugs could potentially prevent the precipitation of a MSG-induced asthmatic attack, while the dis continuation of drugs could be responsible for in creased susceptibility to attacks irrespective of cause. In those cases where the latter scenario was involved, e.g., several cases noted by Allen et al. (1987) in which drugs had been discontinued, the investigators reproduced the MSG effects on sepa rate occasions under controlled circumstances.
De layed responses were also documented by MoneretVautrin et al. (1987) in patients who had been off asthma-related medication for three days. Out of a total of 321 asthmatic subjects across all studies reviewed, 28 could be described as responders to MSG. The Expert Panel concluded that the report of Allen et al. (1987) was a reasonably welldesigned scientific oral challenge study in asthmatic subjects that provided evidence to support the exis tence of a subgroup of asthmatic responders to MSG. (Seefull report?,Chapter VII, D, l for discussion of MSG and asthma.) c. How do dose and time relationships com pare with "self-limited" adverse reactions?
No studies have been performed in which dose and time have been associated. For example, no attempt was made to correlate the size of the doses eliciting responses in either Allen et al. (1987) or Moneret-Vautrin et al. (1987) and the time of onset of symptoms.
The range of dosages producing an effect in the report of Allen et al. (1987) was 0.5 g MSG (n=l) to 2.5 g MSG (n=12). Moneret-Vautrin et al. (1987) reported bronchospasm (n=2) after doses of 2.5 g MSG. Both Allen et al. (1987) and Moneret-Vautrin et al. (1987) used capsules as the challenge vehicle and challenged subjects after an overnight fast.
Temporal data from the report of Allen et al. (1987) indicated an interval of 1-2 hours before onset of asthma and/or the MSG symptom complex in 7 of 32 subjects orally challenged with MSG. Six other subjects did not have the symptom complex but exhibited asthma 6-12 hours post-challenge. The interval before onset of symptoms in these subjects is longer than that of the self-limited ad verse reactions usually described for the symptom complex (15-30 minutes).
The Expert Panel, in reviewing the study by Allen et al. (1987) , noted that data on patient compliance while on the elimination diet were not reported. Although all subjects reportedly were continued on corticosteroid medication and inhaled ÃŸ-adrenergic agonist bronchodilators during the challenge pro tocol, questions about the chronic medication sta tus of the responders prevent any definitive conclu sions about the timing of symptom onset as some of the six patients with delayed onset could conceiv ably have experienced a reaction following the re moval of their theophylline medication. Although they presented data for only one patient, Allen et al. (1987) noted a "reproducibility of the delay after challenge with MSG... observed in all our patients." Similar delayed responses were also documented by Moneret-Vautrin et al. (1987) in patients who had been off medication for three days. The Expert Panel concluded that while the protocol of Allen et al. (1987) was reasonable, these results require in dependent replication in order to rule out the pos sibility of an "off-drug" phenomenon.
(See full re port2, Chapter VII, D, l for more information on MSG and asthma.)
d. Are there predisposing medical conditions associated In the specific reactions?
MSG-induced bronchospasm has been demon strated in some asthmatic patients, but an accurate estimate of the prevalence of asthmatics at risk for MSG-induced asthmatic attacks cannot be ascer tained from available data.
With the possible exception of abnormal vitamin B-6 status, predisposing conditions other than asthma have not been identified. Several schemes are plausible based on the cur rent state of knowledge about glutamate. Such schemes or combinations thereof could be based on conditions of use (i.e., specific types of foods con sumed under defined circumstances), the nature of the physiological response (e.g., MSG symptom complex only, respiratory problems, or gastrointes tinal problems), and/or predisposing factors (e.g., genetic predisposition, physiological condition, nu tritional status, or concurrent drug use). However, insufficient epidemiology data exist which might be used to construct such schemes. Conceivably, a multivariate analysis such as cluster analysis might be applied to a large enough sample of verifiable responders to allow for an identification of specific subgroups of the population who might have a unique group of characterizing features.
Assuming that reproducible associations
Another classification scheme could be based on central versus peripheral effects of ingested MSG. The distinguishing characteristic of central effects would be an elevation in blood glutamate concen trations, perhaps coupled with observable neuroendocrinological changes, e.g., fluctuations in prolactin and cortisol levels. However, such biochemical measures cannot be taken in isolation and must be correlated with symptoms of central effects such as mood changes, dizziness and balance, pain, altered vision, difficulty breathing, and pulse rates. Admit tedly, these symptoms are nonspecific, but efforts to correlate signs and symptoms of central effects under double-blind controlled experimental situa tions are needed. Similarly, additional experimen tation is needed to establish any strong correlations among symptoms and signs of peripheral effects such as gastrointestinal discomfort, fatigue, muscle weakness, chest pain, altered activity levels, blood pressure, pulse rate, and body temperature.
The Expert Panel strongly suggested that the reliability and validity of any classification scheme must be established through vigorous research and statistical corroboration.
(See Response to Question 5, below, and full report2, ChapterIV, Fand Table 5, Chapter V, and Chapter VII, D and Appendix Table 10; Challenge Studies.) 4. Is It possible to classify adverse reactions based upon: a. The length of time after MSG administra tion to the onset of the reactions?
No.Valid data are very limited; the typical re ported interval for the MSG symptom complex is between 15 and 60 minutes; but, in some asthmatic patients (Allen et al., 1987; Moneret-Vautrin, 1987) , it can be up to 6 to 12 hours post-challenge.
(See response to Question 3 above and full report* Chap ter VII, D.) 
b. Dose responsiveness?
No. There are some data from a single-blind challenge of asthmatic subjects (Allen et al., 1987) that support the concept of dose responsiveness. See response to Question 3 above. Additional discus sion of dose responsiveness in terms of central and peripheral effects is provided in the full report2 Chapter VII and in Chapter IX.
c. Type of adverse reaction elicited?
No. These are identified in Question 2 above and in the full report2, Chapter VII, Tables 10 and 11  and Appendix Tables 9 and 10 . See also response to Question 3 above.
d. Predisposing factors?
No. As noted in Question 2, the only predispos ing factor that has been documented is unstable asthma. See response to Question 3 above.
Is It possible to determine the mechanism whereby any glutamate-based
adverse reaction might occur? Additional discussion and docu mentation of mechanisms that are testable ex perimentally would be helpful.
Not at the present time. However, a number of plausible mechanisms could be identified to explain reported adverse effects from MSG ingestion. The majority of potential mechanisms would be medi ated through interaction at the level of either central or peripheral glutamate receptors.
Among the po tential mechanisms are excitotoxicity, stimulation of CNS glutamate receptors that activate neuroen docrine systems, mediate pain, inflammation, blood pressure regulation and respiration, stimulation of peripheral glutamate receptors associated with gas trointestinal motility, respiration, and the endo crine system (e.g., the adrenal glands and the ante rior pituitary gland). To date, no scientifically valid studies have been performed to confirm these hypothesized mechanisms. An expanded discussion of these topics, including suggestions on mechanisms that might be tested experimentally, can befound in thefull report2, Chapters V and IX.
The Expert Panel found that a major constraint in identifying mechanisms has been the inability to make connections between studies of adverse ef fects and those of metabolic response to oral MSG challenges. The former lacked data on objective measures of response, in particular blood glutamate concentrations, while the latter focused on blood glutamate data without evaluation of adverse ef-fects. The animal studies employing both patenterai and enterai challenges that have been used to sup port the possibility of adverse effects have, in gen eral, lacked data on blood glutamate levels. It is difficult to draw conclusions about the relationship between potential adverse effects of enterai MSG challenge in nonhuman primates given the fact that blood data have been rarely reported and none of the relevant reports contains any measure of a neuroendocrine effect. The bulk of the enterai chal lenge studies employing animal models have fo cused on either supporting or refuting the conten tion that neonatal exposure to MSG causes hypothalamic lesions. The vast majority of animal studies using patenterai challenges have used MSG as a probe to explore the function of the arcuate nucleus and other structures close to and within circumventricular areas. With the exception of the studies on severe asthma and a single attempt to examine the possible role of ingested MSG in esophageal pain (Kenney, 1979) , no studies in humans have been designed to explore potential mechanisms of either the MSG symptom complex in toto, individual aspects therein (e.g., headache, warmth, burning etc.), or other problems that have been reported to occur conse quent to ingestion of MSG. Because of the dearth of appropriately designed studies, the Expert Panel could only speculate about potential mechanisms based on disparate sources of information on the physiology of glutamate.
What have other authoritative organizations concluded regarding the potential of MSG to elicit adverse clinical reactions? What Is the basis for their conclusions?
Between 1978 and 1992 five authoritative scien tific organizations have published statements on the potential of MSG to elicit adverse reactions. These include the Select Committee on GRAS Substances (1978a,b; 1980a,b) While the five organizations are recognized as prestigious and preeminent entities within their respective disciplinary areas, the published state ments are not equally authoritative scientifically.
The Select Committee on GRAS Substances (SCOGS) of the Federation of American Societies for Experimental Biology published four mono graphs (1978a,b; 1980a,b) that evaluated the then extant literature supporting or questioning the con tinuation of generally recognized as safe (GRAS) food ingredient status of MSG and protein hydrolysates. The four SCOGS reviews are the only ones that include documentation of the scientific litera ture on which the conclusions were based. In regard to MSG, in 1978 SCOGS concluded that continued GRAS usage was acceptable for individuals beyond infancy, but that uncertainties required additional studies. In 1982, SCOGS concluded that, at the then-current levels of use, MSG posed no hazard, but noted that the Committee could not determine without additional data if increased consumption would be hazardous.
With regard to protein hydrolysates, SCOGS concluded in 1978 that, at the estimated use levels, soy sauces were safe; however, if consumption in creased, additional data would be needed to con firm this conclusion. With regard to acid and enzymatically hydrolyzed protein and yeast autolysates, use at then-current levels as a GRAS substance was acceptable for individuals beyond infancy, but some uncertainties required additional study. Based on evaluation of additional data, in 1982 SCOGS con cluded that protein hydrolysates could be contin ued as GRAS substances.
The Joint FAO/WHO Expert Committee on Food Additives published a report based on an extensive review of scientific literature on MSG in 1991. As with most reports of Joint FAO/WHO Expert Committees, the scope and extent of scien tific studies examined are not fully documented. The Committee did not set an acceptable daily intake (ADI), but stated that several glutamate salts including MSG were "of low toxicity" and did not constitute a human health hazard as a result of their use to achieve technical effects (flavoring agents). The absence of additional statements on MSG or on protein hydrolysates since 1991 is puzzling in view of the ongoing controversy concerning adverse re actions.
In 1991 the Commission of the European Com munities concluded that no specific toxic effects were evident in various animal models except for varying vulnerability of neonatal rodent central ner vous systems where "massive doses" were adminis tered. The Commission also noted reports of ad verse reactions in humans who ingested doses of over 3 g but stated that such reactions occurred with foods not containing glutamates and that no objec tive clinical measurements were associated with re ported symptoms. The Commission review was based on selective reviews and evaluations of scien tific literature submitted to or commissioned by the group. These sources are not fully documented.
In 1992 review of scientific literature from 1987 to 1992. The IFT did not identify the scientific literature cited in reaching its conclusions. The IFF paper stated that, for the vast majority of persons, MSG is safe, that adverse reactions do occur but these are exceptions rather than the rule, that sensitive per sons should seek medical advice and controlled challenge tests, and that foods to which MSG is added should be so labeled. The IFT also recom mended additional research (i.e., double-blinded challenge tests under controlled conditions) to clar ify the association of MSG with adverse reactions.
In 1992 the Council on Scientific Affairs of the American Medical Association stated that L-glutamate in any form had not been shown to be a "significant health hazard" and supported the exclu sion of labeling glutamate derived from protein hydrolysate products. This publication was an his torical review of regulatory status and position pa pers prepared by WHO, the IFT, and a literature review by the International Glutamate Technical Committee (1991). This position paper does not provide evidence of an independent rÃ©Ã©valuation of the scientific literature by the American Medical Association Council on Scientific Affairs.
In summary, only the four evaluative reviews of the SCOGS provide complete documentation of the scientific literature used in reaching the "authorita tive" position. The other four authoritative organi zations have published position statements that, in general, reach analogous positions; however, in re trospect, documentation of the scope and extent of scientific literature evaluated is lacking.
7.a. What are the free glutamate levels In food containing hydrolyzed vegetable protein (HVP) as used In the range of products manufactured for consumption by American consumers?
The acid hydrolysis process produces a mixture of amino acids that reflects the composition of the intact protein except that tryptophan is destroyed while cysteine and methionine concentrations are markedly reduced. The glutamate content of com mercial products, on a dry weight basis, expressed as glutamic acid, ranges from 5.6% to 14.17%. The International Hydrolyzed Protein Council specified an upper limit for glutamic acid of 25% for acid hydrolyzed protein (Select Committee on GRAS Substances, 1978b).
More recent analyses (Krukar, 1993; Patti, 1993) Only two reports were found that addressed the potential adverse effects of glutamate contained in protein hydrolysates; however, only the study by Olney et al. (1973) specifically evaluated the adverse effects of glutamate contained in hydrolyzed pro teins. The study by Stegink et al. (1974) made ex trapolations based on comparisons between blood glutamate concentrations obtained in their own feeding study and the blood glutamate and histological findings of Olney et al. (1973) . Olney et al. (1973) reported lesions in the hypothalamus of 10-day-old mice given enzymatic casein hydrolysate subcutaneously at doses ranging from 1 to 5 g per kg body weight. These experiments used enzymatically hydrolyzed casein. Assuming that the free glu tamic acid content of casein hydrolysates is 25 g per 100 g of amino acids (the upper level specified by the International Hydrolyzed Protein Council [Se lect Committee on GRAS Substances, 1978b]), then lesions occurred in neonatal mice receiving total free glutamate doses of 1.5 to 7.5 mg (sample calcu lation: a dose of 5 mg per g body weight x 6 g body weight/mouse x 25% = 7.5 mg). No such effects have been reported from studies of other animal species; no adverse effects have been reported in studies employing enterai chal lenge. No comparable human data are available.
While parenteral feedings in humans may involve the use of hydrolyzed proteins, the Expert Panel was unaware of any studies that have been performed to assess the potential for adverse effects specifically attributable to the glutamate contained in these mixtures. Moreover, the relevance of these findings to potential adverse effects in humans under nor mal conditions of ingestion is unclear.
The Expert Panel found no scientific reports of glutamic acid-related adverse effects of ingesting either protein hydrolysates of microbial, vegetable, or animal origin.
Of the 154 testimonial letters received by LSRO as of July 1, 1994, only one correspondent men tioned hydrolyzed vegetable protein (HVP) as a likely cause of symptoms, and this was HVP con tained in a skin moisturizing preparation (Moore, 
In view of these calculations and the lack of reports of adverse reactions, it is unlikely that life-threatening reac tions would result from normal patterns of consumption of products containing HVP. (See full report2, Chapter III, B, 2 and Chapter VII, A).
d. Explain more fully the relevance of data on subcutaneous administration of HP to mice to the oral administration of HP and MSG. Can a dose relationship or comparison be made be tween the quantity of MSG In foods containing HP and glutamate per se be made?
Other than the study of Olney et al. (1973) cited above, there are no relevant data that establish a relationship between subcutaneous administration of HP to mice and oral ingestion of HP and MSG by humans. Consequently, a dose relationship can not be determined in humans. See full report^, Appendix Table 6 for a summary of Olney et al. (1973). 8. Are there any defined human subgroups that are more susceptible to glutamate than the gen eral population? Expand the discussion of the extent and possible bases of similarities and differences among subjects Ingesting MSG or placebos In regard to reported adverse reactions.
There is limited evidence that some asthmatic patients are more likely to suffer adverse effects than members of the general population. As men tioned previously, the Expert Panel's review of the literature revealed several possible situations in which subgroups of the general population might be identified who may be more susceptible to the effects of MSG. These groups include individuals with either vitamin B-6 malnutrition, infants (in utero and newborns), women taking oral contracep tives, and individuals with affective disorders. Each of these possibilities has been discussed in Chapter V and Chapter VII, in addition to questions involv ing the predisposing conditions addressed above. Again, the Expert Panel emphasized that, in the face of a complete lack of studies addressing these con tingencies, any statements about the potential in crease in susceptibility in these subgroups to ad verse effects from the ingestion of MSG are specu lative at this time.
In order to be comprehensive, the Expert Panel recognized that there exists in the medical literature on idiosyncratic reactions and "food allergy" anec dotal reports of manifestations frequently identified as being typical of MSG sensitivity. For example, idiosyncratic responses are well known in persons with non-immunologic food intolerance and sub jects in food challenge trials who react to placebos. Moreover, the reported symptoms resemble those that FDA has observed since 1983 in its tracking system on symptoms and signs allegedly resulting from consumption of aspartame. The symptoms also resemble those observed in military subjects when the nature of the macronutrient content of the diet is precipitously changed as in military test ing of new field rations (Schnackenberg et al., 1986) . Thus, it is reasonable to conclude that sub groups do exist who are more likely to experience adverse reactions to foods and food ingredients, including glutamate, than is the general population of consumers.
However Available data suggest strongly that precipitation of adverse reactions is most likely to occur when the dose is given in the fasting state as a liquid or capsule without food. An adverse reaction has been re ported in one subject who received a single dose of 0.5 g of MSG, and it is therefore suggested that double-blind, placebo-controlled testing begin with this dose. In subjects with no reaction to 0.5 g, an additional test with 3 g should be carried out. Test ing at greater doses is probably not needed because it is unlikely that subjects who fail to react to a dose of 3 g given under fasting conditions will react to the quantities of glutamates consumed with food under "real-life" circumstances.
b. What study designs are appropriate for testIng MSG mediation of different types of re ported adverse reactions?
The most appropriate study design for challenge tests is a double-blind placebo-controlled protocol as outlined by Bock et al. (1988) and the Workshop on Adverse Reactions to Food and Food Additives (Metcalfe and Sampson, 1990) or a more rigorously controlled alternative thereof. For confirmation of the symptom complex, double-blind placebo-con trolled challenges on separate occasions must re produce symptoms with the ingestion of MSG and produce no response with the placebo. For confirmation of an objective response, e.g., bronchoconstriction in asthmatic patients, a single, double-blind, placebo-controlled challenge with re sponse to MSG and nonresponse to placebo would be sufficient.
All of the above challenge tests should be con ducted in appropriately uniform settings with stan dardized procedures.
Emergency medical service capabilities should be available immediately adja cent to the setting.
In addition to the challenge tests, objective phys iological and psychometric tests should also be ap plied. For example, tests could include complete neurological examination, blood tests (for amino acid levels and standard parameters, e.g., glucose, insulin, vitamin B-6 status indices, etc.) and psycho metric assessments including mood scales, etc. In addition, consideration should be given to inclusion of functional imaging techniques (e.g., PET scan) and/or recording of visual or auditory evoked po tentials, and measures of physiological stress, e.g., circulating cortisol levels and skin conductivity, should be considered.
H.a. During testing for MSG mediation of each class of adverse reactions, what Is the best man ner to control for various possible disease trig gers?
All subjects involved in any double-blind placebocontrolled challenge testing should have a complete medical history and examination prior to testing. Subjects should be segregated into population sam ples on the basis of these screening criteria, e.g., chronic asthma, diagnosed food allergies, abnormal vitamin B-6 status, etc.
b. What are the appropriate subject selection criteria?
To determine the prevalence of adverse reactions to glutamates in the general population, the fre quency of adverse reactions should be determined in patients with asthma and in randomly chosen individuals without asthma.
Vitamin B-6 status should be determined in both groups. In addition, it may be useful to determine the prevalence of adverse reactions to glutamates in individuals with self-reported history of adverse reactions to gluta mates. These individuals should also be classified with regard to the presence or absence of asthma and vitamin B-6 status should be determined.
(See additional discussion infoltÃ¬report2, Chapter VIII.)
c. Can the test solution be adequately blinded?
Liquid or capsule forms can be blinded ade quately. As noted in the discussion in Chapter VIII, the placebo must be indistinguishable from the active agent (MSG-containing vehicle), but not nec essarily perceived as identical. Investigators must validate the placebo by demonstrating that an inde pendent panel was unable to distinguish the "active" from "placebo" agent in a pilot testing procedure prior to initiation of the actual protocol. 
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The Expert Panel recognized that the use of capsules ensures the greatest control over dose and blinding; however, the Expert Panel also noted that the use of capsules obviates the potential role of the oral cavity and esophagus in the precipitation of potential adverse effects. The Expert Panel sug gested that the use of capsules versus liquids would depend on the goal of the study. For example, if the goal is to study the potential for adverse effects of MSG ingestion under conditions of normal use, a liquid vehicle would be most appropriate.
The Ex pert Panel also noted the report by Stegink et. al. (1979) in which marked differences in peak plasma glutamate concentrations were found when MSG was delivered in capsules rather than liquid vehicles. (Administration in capsules resulted in a 3-to 4-fold attenuation of peak glutamate response.) e. What sample size Is needed to assure that adequate sensitivity Is present to detect an effect or the absence of an effect?
The double-blind placebo-controlled protocols outlined above are sufficiently rigorous to preclude the possibility that one laboratory, at one time, could identify sufficient subjects who would be will ing to participate in such challenge tests. In a prac tical sense, such experiments will need to be con ducted at several locations over a period of several years in a collaborative effort. Thus, it seems that actual sample size is less of a factor than the number of subjects and number of challenges at several locations over an extended period. Multivariate analyses of data will be required to confirm statisti cal significance of challenge test results. At a mini mum, the absence of reaction of any parameter in 40 subjects with suggestive history would provide a 95% confidence level. This estimate is based on a power analysis designed to compute the number of subjects in a study employing a nominal (e.g., yes/no, +/-) response paradigm utilizing a binomial distribution.
f. Given the possibly high Incidence of subjec tive symptoms Inadverse reactions, additional discussion of study parameters such as statis tical aspects of sample size Is warranted.
As noted by Rosenzweig et al. (1993) in a review of controlled trials involving over 1200 subjects, adverse events were reported by about 20% of the subjects when placebos were administered. Conse quently, multiple double-blind placebo-controlled food challenges (DBPCFC) will be necessary to con firm subjective symptoms. Based on the following mathematical relationships, five DBPCFC may be necessary to conclude that subjective symptoms (e.g., headache, chest tightness, numbness, etc.) are secondary to MSG in a highly suggestible individual.
This assumes a binomial distribution of a nominal response. Therefore, with a one-in-two chance of a positive response with each challenge, 5 positive responses to MSG with all negative responses to placebo could occur in 1 of 32 chances, or p=0.03.
In subjects not considered highly suggestible, one could assume a false positive rate of 20% to 25% as suggested by Rosenzweig et al. (1993) . In such cases, three DBPCFC would be necessary to confirm the association of subjective symptoms and MSG (i.e., one in four chance cubed [1/4^] or p < 0.02).
In patients with objective findings following MSG challenge (e.g., marked bronchospasm, anaphylaxis, vomiting, etc.), a single DBPCFC can be re garded as definitive. (Seefull report2, Chapter VIIIfor further discussion of issues in experimental design.)
What are the relative sensitivities of rodents and nonhuman primates to the acute central nervous system (CNS) effects of MSG?
The Expert Panel found no scientific studies that carefully assessed the relative sensitivities of both rodents and nonhuman primates to the central nervous system effects of MSG. However, numer ous studies have shown that doses of 0.5 to 4.0 g MSG/kg body weight produce hypothalamic le sions in infant mice. For enterai administration, the minimum effective dose is 0.5 to 0.7 g MSG/kg body weight (Daabees et al., 1985; O'Hara and Takasaki, 1979; Olney and Ho, 1970) . Similarly, Olney et al. (1972) described "small focal lesions" in the brains of infant rhesus monkeys given 1 to 2 g MSG/kg body weight enterally (by gavage) in a 50/50 solu tion of water and skim milk. Based on these few studies, the Expert Panel concluded that the relative sensitivities of rodents and nonhuman primates to enterai MSG-induced brain lesions are likely to be of the same order of magnitude.
The Expert Panel noted that pharmacokinetic comparisons between species assume a similar in herent sensitivity of brain to fluctuations in concen trations of either plasma glutamate or brain extra cellular glutamate consequent to MSG exposure. The Expert Panel was unaware of any data to sup port that contention. It is conceivable that the inher ent susceptibility of brain may differ across species, regardless of peripheral pharmacokinetic or bloodbrain barrier (BBB) effects. The Expert Panel re ferred to the study of McDonald and Johnston (1990) that reported that the susceptibility to extra cellular glutamate varies markedly in rat brain slices during development. Consequently, it may have no meaning to compare doses in different species that give a certain peak plasma concentration until the inherent sensitivity of the brain has been deter mined for multiple species and across varying devel opmental periods. Additional work is required with The evidence linking glutamate challenge with changes in pituitary function was found in the ex tensive literature on parenteral exposure of animal models, primarily rodents, but also in monkeys (see full report^, Appendix Table 7 ). Two classes of pituitary response to parenteral glutamate have been observed: chronic changes following neonatal glutamate-induced lesions of the hypothalamus, and acute effects following glutamate challenge later in development.
The former have been stud ied only in rodents. With regard to the latter, which do not appear to involve the neurotoxic actions of glutamate, numerous studies have demonstrated discrete elevations in gonadotropin, prolactin, ACTH, and growth hormone in rodents and nonhuman primates consequent to s.c., i.p., or i.V. ex posure to glutamate. Good evidence exists to indi cate that the ability of glutamate to elicit pituitary hormone secretion is mediated largely by an indi rect action on the hypothalamus where the amino acid stimulates hypophysiotropic neurons to release their release/release-inhibiting hormones into the hypophyseal portal circulation.
The Expert Panel found no studies in which levels of pituitary hormones (or hormones from the target glands) were assessed in enterally challenged ro dents or nonhuman primates (See full report^, Ap pendix Tables 4 and 5 ). However, in rodents, enteral challenge has been associated with behavioral changes such as decreased activity levels, cognitive deficits, neurochemical changes, convulsions, changes in appetite regulation, and increased pitu itary gland weights. While several of these findings would presumably involve neuroendocrine changes, no studies have been found that have specifically documented anomalies in neuroendocrine function, e.g., changes in circulating hormone levels, in enterally challenged rodents. Carlson et al. (1989) examined the potential of several amino acids including 10 g of glutamic acid and 10 g aspartic acid (aspartate and glutamate challenges given on separate days) to influence pi tuitary function in humans (see summary in full report^, Appendix Table 10 ). In addition to groups receiving glutamate and aspartate (n=l 1 and 9, re spectively), subjects received taurine capsules, and two doses of cysteine (5 and 10 g) also in gelatin capsules. Subjects were challenged with these amino acids on separate days. As the intention was to assess the impact on prolactin, which normally peaks at midday, no attempt was made to maintain an over night fast prior to the challenges (Carlson, 1993) . Carlson et al. (1989) reported significant in creases in both serum prolactin and cortisol after glutamate challenge. They observed that the time of peak levels relative to challenge coincided with peak plasma glutamate concentrations.
Mean baseline values of prolactin (6.6 ng/ml) and cortisol (6.6 nmol/dL) increased to peaks of 12.9 ng/ml and 12.6 fimol/dL, respectively, 1 hour post-challenge with glutamate. Carlson et al. (1989) observed no changes in serum levels of growth hormone, TSH, or LH following either glutamate or aspartate chal lenge. Similarly, no changes in either cortisol or prolactin were noted after aspartate.
The Expert Panel was aware that the study by Carlson et al. (1989) had been preceded by a study in which similar results, i.e., elevations in serum prolactin and cortisol, had been elicited by dietary protein (Carlson et al., 1983) . While it would be a simple matter to attribute the rise in cortisol and prolactin to protein or generically to amino acids, the Expert Panel noted that no such rise occurred following aspartic acid or any of the other amino acids tested by Carlson et al. (1989) . Consequently, while it is possible that the effect on cortisol and prolactin could be a result of protein consumption, it is also possible that the effect seen by Carlson et al. (1983) was due to the glutamate content of the protein meal. As noted by Carlson (1994) , "It is difficult to reach a definite conclusion, since in no study was there a direct comparison of the cortisol responses to glutamate and to mixed or protein meals in the same subjects." Carlson (1994) also acknowledged that similar responses in both serum cortisol and prolactin have been documented fol lowing physical and mental stress.
The Expert Panel concluded that the report by Carlson et al. (1989) , while not definitive proof of a direct neuroendocrinological response to ingested MSG, does offer evidence for the potential for such a reaction. Consequently, this possibility must be considered plausible in the absence of contradictory evidence, particularly in light of the irrefutable evi dence supplied by the animal studies of an effect of parenterally administered MSG on these hormones. The Expert Panel strongly recommends that future studies be designed to replicate and further explore this effect in humans.
b. What controls were used to demonstrate that this effect was specific to MSG and not related to nonspecific changes in such factors as plasma pH or osmolarity?
The Expert Panel was convinced that MSG given parenterally to neonatal animals at sufficient doses (between 2 and 4 g MSG/kg body weight in rodents and > 6 g MSG/kg body weight in hamsters, in single repeated daily doses) will cause long-term changes in the neuroendocrine axes governing pituitary hor mone secretion. In addition, equally convincing evidence is available demonstrating that parenteral glutamate administration to adult animals (mon keys and rodents) stimulates the secretion of many pituitary hormones. The majority of studies have used isomolar concentrations of saline to control for the potential effects of sodium in the MSG challenge and have clearly established that the ef fects are due to the glutamate and not the sodium or changes in osmolarity or pH (see full report^, Appendix Tables 6 and 7) . Also, acute pituitary hormone release in response to glutamate and re lated amino acid analogs may be blocked by con comitant administration of specific glutamate re ceptor antagonists (see response to question 14c, below; full report2, Chapter V and discussion of glutamate receptor antagonists in Chapter VI, C).
c. What evidence is provided that specific ex citatory neurotransmltter receptors are In volved In any effect observed?
Numerous studies in rodents and nonhuman primates have made the link between release of hormones, including luteinizing hormone, prolactin, hypothalamic gonadotropin-releasing hor mone, follicle-stimulating hormone, and specific excitatory neurotransmitter receptors, particularly the NMDA receptor (Abbud and Smith, 1991; Arslan et al., 1988; Gay and Plant, 1987; Gay and Plant, 1988; Plant et al., 1989; Wilson and Knobil, 1982 (Carlson et al., 1989) . In the monkey, intravenous glutamate injections of 48 mg MSG/kg body weight, and greater, have been reported to elicit luteinizing hormone release. Although plasma glutamate levels achieved follow ing the threshold dose of 48 mg glutamate/kg body weight were not measured, an intravenous injection of 150 mg glutamate/kg body weight in this species produced circulating levels of glutamate between 4,000 and 6,000 nM. Therefore, if intravenous glu tamate dose and circulating glutamate concentra tions are linearly related, it may be suggested that an estimate of threshold circulating glutamate con centration for luteinizing hormone release in the monkey is 1,000 to 2,000 b.What Is the probability of MSG Ingestion with foods Influencing the release of pituitary hormones?
The Expert Panel concluded that it is unlikely, but possible, that ingestion of MSG with foods could cause the release of pituitary hormones.
Studies have been performed in both animals and humans that support the contention that glutamate given in a liquid medium, i.e., water or clear broth, to a fasted subject will result in higher circulating con centrations of glutamate than when glutamate is given with a mixed meal or food matrix, e.g., liquid formula (see full report?, Chapter IV, Table 5 ). No studies have been performed that have attempted to link blood levels to effects other than hypotha lamic lesions in neonatal animals. Few of the paren teral challenge studies have linked the lesions or neuroendocrinological effects observed to circulat ing levels of glutamate. Moreover, no studies have been found that have measured both blood levels of glutamate and related amino acids and either luteinizing hormone or any other neuroendocrine parameter in nonhuman primates orally exposed to MSG.
Any conclusions expressed by the Expert Panel about the relationship between ingestion of MSG with food and alterations in the release of pituitary hormones in nonhuman primates would be specu lation. The data available to the Expert Panel were insufficient to support the contention that eleva tions in plasma glutamate concentrations per se are the sine qua non of adverse effects from glutamate.
16.a. What are the relative effects of treatment conditions, or circumstances of oral Ingestion, on the plasma concentrations of MSG, e.g., does
AfSG given in water produce a different plasma level of glutamate than the same dose given In a more complex food matrix containing carbohy drates?
Evidence summarized in the full report^, Chap ter IV, Table 5 and Appendix Tables 2 and 3 , clearly demonstrates that the composition of the challenge vehicle and the conditions of challenge, e.g., fed versus fasted, significantly impact on changes in circulating glutamate in response to an oral chal lenge. The extent of the rise in plasma concentra tions of glutamate and related amino acids is af fected by a number of factors including the size of the dose (increase with increasing dose); the nature of the challenge vehicle (e.g., water causes greater rise than mixed meal); the temporal proximity of food consumption (fasted subjects have greater re sponse than those challenged with a meal); and macronutrient composition of concurrent food (carbohydrate and mixed meals have an attenuating effect compared with fasting or protein). The Ex pert Panel noted that no data are available on the impact of a 15-to 20-minute delay between chal lenge in a liquid broth as would be consumed in the beginning of a meal and consumption of a mixed meal on blood glutamate concentrations or mani festation of adverse effects.
As summarized in the full report^, Chapter IV, Table 5 , available data do support an incremental increase in plasma glutamate concentrations conse quent to increasing doses of MSG in water in adult humans. A total of five studies were identified in which adults received MSG in water only. Doses in these studies ranged from 60 to 150 mg MSG/kg body weight and responses in terms of peak gluta mate concentrations ranged from 155 nM (at 60 mg dose) to 718 nM (at 150 mg/kg).
b. What Influence does strength of MSG con centration and mode of administration (human sipping versus animal gavage) have on plasma levels of glutamate?
The Expert Panel was unaware of any studies examining potential adverse effects of MSG in hu mans that have addressed the impact of the mode of administration (e.g., sipping) on circulating glu tamate concentrations. Similarly, no studies have been performed that compare relative impact of sipping in humans versus gavage in animals. How ever, it should be noted that the majority of the human studies reviewed by the Expert Panel en deavored to ensure that subjects consumed the challenge vehicle within a prescribed time limit. In animals, the vast majority of studies of enterai MSG challenge used the gavage method as opposed to self-selection. No studies were found that com Only two published reports evaluated the meta bolic response to ingested glutamate in human in fants (Stegink et al., 1986; Tung and Tung, 1980) . As the report by Tung and Tung (1980) contained highly variable data sets in a sample of infants that included two premature infants, the Expert Panel concluded that the study by Stegink et al. (1986) contained more useful information. Stegink et al. (1986) randomly assigned 8 infants (mean age 10 months) to receive consommÃ©(with 56 mg MSG/8 oz or 4.1 mg/kg when 160 ml is fed to a 9.1 kg infant) containing either 0, 25, or 50 mg MSG/kg at 1-week intervals. All challenges occurred at 0800 hours after an overnight fast.
Infants were randomly assigned to one of two blood collection schedules 0, 30, 60, and 120 min utes and 0, 15, 45, and 90 minutes; each group had four infants. Infant data were compared with the adult data from Stegink et al. (1985) . Whereas in the previous study with adults given 15 minutes to con sume the challenge soup (mean time of consump tion was 7 minutes), infants in this study took a mean of 18 minutes to consume the soup.
Infants had significantly higher baseline levels of both aspartate and glutamate and demonstrated a different pharmacokinetic response to challenge with both 25 and 50 mg MSG/kg when compared with previously studied adults. Baseline glutamate and aspartate levels were significantly lower in adults at all levels of challenge (glutamate: 36.9, 39.3, and 37.7 fimol/L versus 62.4, 72.2, and 67.1 nmol/L; aspartate 7.0, 6.6, 4.3 nmol/L versus 12.5, 15.0, and 15.9 Mmol/L at 0,25, and 50 mg MSG/kg, respectively). Peak infant glutamate levels at 25 mg/kg dose occurred at 15 minutes (106 nmol/L) versus at 30 minutes in adults (102 nmol/L). Peak aspartate levels occurred at 45 minutes in infants (21.1 jimol/L) and 30 minutes in adults (11.2 nmol/L). Similarly, at 50 mg/kg dose peak infant glutamate levels occurred at 15 minutes (120 jimol/L) versus at 30 minutes in adults (170 nmol/L). Peak aspartate levels occurred at 45 minutes in infants (22.9 fimol/L) and 30 minutes in adults (14.0 jimol/L). No changes in erythrocyte glutamate or aspartate levels relative to baseline levels were noted in the infants at any dose level.
No data were provided with regard to method of infant feeding, i.e., breast-versus bottle-fed. Differ ences in the timing of consumption of the soup and blood sampling between the infants and adults could have been reflected in the pharmacokinetic differences in this report, i.e., glutamate levels peaked sooner and aspartate levels peaked higher and later in infants than in adults. There were no reported adverse effects.
Results of animal studies indicate that sensitivity to CNS effects of exogenous MSG decreases follow ing the neonatal period; however, large doses given parenterally can induce CNS damage in juvenile and adult animals.
What have other authoritative organiza tions concluded regarding the potential of MSG to elicit neurotoxlc reactions? What are the bases for their conclusions?
None of the previous reports by other authorita tive organizations has made the distinction between adverse effects associated with peripheral and/or CNS effects of MSG and those resulting specifically from neurotoxicity, i.e., effects associated with le sions. The conclusions of these organizations, as outlined in the response to Question 6, imply an absence of data to support a neurotoxic effect from MSG at levels required to produce a flavor-enhanc ing effect. The response to Question 6 includes a discussion of the basis of the conclusions of these organizations.
With regard to a role of MSG in producing adverse effects in humans, the Expert Panel con cluded that there is sufficient evidence to support the existence of a subgroup of the general popula tion of otherwise healthy individuals who may re spond to large doses ( > 3 g) under specific condi tions of use (see Questions 1 and 2). In addition, there may be a small subgroup of previously diag nosed unstable asthmatics who also may respond to large doses of MSG under specific conditions of use (see Questions 1, 2, and 3). The mechanisms of these reactions are unknown at this time; however, no evidence exists to support the ability of orally ingested glutamate to produce neurotoxic or lesioning effects in humans.
The Expert Panel noted that any differences in its conclusions from those reached by other author itative organizations are based on the documented exhaustive nature of its literature review (see full report2, Literature Cited). As opposed to organiza tions other than the SCOGS Committee, who per formed a similarly thorough review of the existing literature, the Expert Panel relied solely on its own interpretations of the extant data. Differences be tween the conclusions of the SCOGS and the Expert Panel are due to the publication of literature since 1980 that is related to the evolving knowledge about glutamate neurobiology and neurophysiology. 
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